Last reviewed · How we verify

ayesha tariq — Portfolio Competitive Intelligence Brief

ayesha tariq pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
intravenous levetireacetam intravenous levetireacetam marketed Antiepileptic agent SV2A (synaptic vesicle protein 2A) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Children's Hospital of Fudan University · 1 shared drug class
  2. Generic (originally UCB Pharma) · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Hospices Civils de Lyon · 1 shared drug class
  5. Mario Negri Institute for Pharmacological Research · 1 shared drug class
  6. Richard H. Haas · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ayesha tariq:

Cite this brief

Drug Landscape (2026). ayesha tariq — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ayesha-tariq. Accessed 2026-05-16.

Related